Comparable stake leader
Velan Capital Investment Management LP
SEC ownership of Jasper Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001788028.
Disclosed value leader
Velan Capital Investment Management LP
Comparable rows
49/50
Latest evidence
30 Jun 2026
- Public ticker
- JSPR, JSPRW on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Velan Capital Investment Management LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
49 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Velan Capital Investment Management LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001788028
- Issuer location
- Redwood City, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Jasper Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Velan Capital Investment ...
Disclosed value leader
Velan Capital Investment ...
Comparable rows
49/50
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 9.9%
1 rows are not safely comparable across share classes.
13D/G row: Velan Capital Investment Management LP
Showing 1-8 of 50 holder rows.
Quick read
Velan Capital Investment Management LP leads the comparable SEC ownership view at 9.9%.
49 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Velan Capital Investment Management LP's linked filing trail.
Comparable ownership
Top 5
Velan Capital Investment Manageme...
9.9%
T. Rowe Price Investment Manageme...
7.1%
ACORN BIOVENTURES, L.P.
5.3%
MORGAN STANLEY
4.8%
KINGDON CAPITAL MANAGEMENT, L.L.C.
4.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP |
3/4/5
13D/G
13F
10%+ Owner · Company
|
9.9%
from 13D/G
|
$18,568,073
1,433,828 shares
|
— | 08 Feb 2024 |
| T. Rowe Price Investment Management, Inc. |
13D/G
|
7.1%
|
$4,897,117
2,057,612 shares
|
$0 | 30 Sep 2025 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
5.3%
|
$2,660,821
1,486,492 shares
|
-$537,000 | 23 Jan 2026 |
| MORGAN STANLEY |
13D/G
13F
Company
|
4.8%
|
$1,226,746
1,333,420 shares
|
-$585,456 | 31 Mar 2026 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. |
13D/G
13F
Company
|
4.7%
|
$3,153,131
1,324,845 shares
|
+$1,332,431 | 30 Sep 2025 |
| Carlyle Group Inc. |
3/4/5
13D/G
13F
Former 10% Owner · The Carlyle Group Inc. · Company
|
3.8%
from 13D/G
|
$13,807,148
1,066,189 shares
|
— | 08 Feb 2024 |
| Qiming U.S. Healthcare Fund II, L.P. |
3/4/5
13D/G
10%+ Owner
|
3.3%
from 13D/G
|
$5,525,844
8,519,648 shares
|
— | 27 Jan 2023 |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
Millennium Management LLC
|
1.7%
|
$228,859
486,933 shares
|
-$536,778 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$347,490.
Buys
$347,490
Insiders: 4
Sells
$0
Insiders: 0
Net
+$347,490
Shares: +143,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 143,000
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 143,000 | 0 | $347,490 | $0 | +$347,490 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Jasper Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
Velan Capital Investment Management LP
Net 12M change
+$347,490
Latest report
31 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 10%+ Owner | $18,568,073 | Mixed | 08 Feb 2024 | ||
| Carlyle Group Inc. | Former 10% Owner | $13,807,148 | Filing P/S | 08 Feb 2024 | ||
| Qiming U.S. Healthcare Fund II, L.P. | 10%+ Owner | $5,525,844 | Mixed | 27 Jan 2023 | ||
| ROCHE HOLDING LTD | 10%+ Owner | $2,950,874 | Mixed | 25 Jan 2023 | ||
| Howard I. Hoffen | Former Director | $1,491,780 | Mixed | 24 Sep 2021 | ||
| Balaji Venkataraman | Former Director And Officer | $1,491,780 | Mixed | 24 Sep 2021 | ||
| Amplitude Healthcare Holdings LLC | 10%+ Owner | $1,491,780 | Mixed | 24 Sep 2021 | ||
| Kenneth F. Clifford | Former Officer | $1,491,780 | Mixed | 24 Sep 2021 | ||
| Patrick J. Crutcher | Director | $454,161 | Mixed | 31 Jul 2026 | ||
| Judith Anne Shizuru | Director | $381,269 | +$99,630 | +35% | Filing P/S | 31 Jul 2026 |
| Ron Martell | President, CEO and Director, Director | $180,106 | +$99,630 | +124% | Filing P/S | 02 Jan 2026 |
| Thomas G. Wiggans | Director | $113,830 | +$99,630 | +702% | Mixed | 31 Jul 2026 |
| Svetlana Lucas | Director | $48,600 | +$48,600 | +100% | Filing P/S | 31 Jul 2026 |
| William Lis | Director | $34,714 | Mixed | 13 Oct 2023 | ||
| Wenru Song | EVP, Head of R&D | $2,760 | Mixed | 16 Jul 2026 | ||
| Edwin Jonathan Tucker | Chief Medical Officer | $1,669 | Mixed | 04 Jun 2025 | ||
| Herb Cross | Chief Financial Officer | Mixed | 02 Jan 2026 | |||
| Anna Louise French | Director | Mixed | 06 Jun 2024 | |||
| Kevin N. Heller | Executive Vice President, Research and Development | Mixed | 21 Mar 2022 | |||
| Chris Nolet | Director | Mixed | 03 Jul 2025 |
Recent insider transactions for Jasper Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas G. Wiggans | JSPR | Stock Option (Right to Buy | Award | 7,500 | 7,500 | 31 Jul 2026 | Direct | |||
| Svetlana Lucas | JSPR | Stock Option (Right to Buy | Award | 7,500 | 7,500 | 31 Jul 2026 | Direct | |||
| Patrick J. Crutcher | JSPR | Stock Option (Right to Buy | Award | 7,500 | 7,500 | 31 Jul 2026 | Direct | |||
| Emster Kurt von | JSPR | Stock Option (Right to Buy | Award | 7,500 | 7,500 | 31 Jul 2026 | Direct | |||
| Judith Anne Shizuru | JSPR | Stock Option (Right to Buy | Award | 7,500 | 7,500 | 31 Jul 2026 | Direct | |||
| Matthew E. Ros | JSPR | Non-Voting Convertible Preferred Stock | Purchase | 881 | 881 | 20 Jul 2026 | Direct | |||
| Patrick J. Crutcher | JSPR | Non-Voting Convertible Preferred Stock | Purchase | 888 | 888 | 20 Jul 2026 | Direct | |||
| Patrick J. Crutcher | JSPR | Stock Option (Right to Buy | Award | 15,000 | 15,000 | 16 Jul 2026 | Direct | |||
| Jeetinder Singh Mahal | JSPR | Stock Option (right to buy) | Award | 500,000 | 500,000 | 06 Feb 2026 | Direct | |||
| Ron Martell | JSPR | Stock Option (right to buy) | Award | 234,000 | 234,000 | 02 Jan 2026 | Direct | |||
| Jeetinder Singh Mahal | JSPR | Stock Option (right to buy) | Award | 90,000 | 90,000 | 02 Jan 2026 | Direct | |||
| Herb Cross | JSPR | Stock Option (right to buy) | Award | 90,000 | 90,000 | 02 Jan 2026 | Direct | |||
| Thomas G. Wiggans | JSPR | Voting Common Stock | Purchase | $99,630 | $2.43 | 41,000 | 41,000 | 22 Sep 2025 | By Wiggans Living Trust | |
| Thomas G. Wiggans | JSPR | Common Stock Warrant (right to buy) | Purchase | 41,000 | 41,000 | 22 Sep 2025 | By Wiggans Living Trust | |||
| Svetlana Lucas | JSPR | Voting Common Stock | Purchase | $48,600 | $2.43 | 20,000 | 20,000 | 22 Sep 2025 | Direct | |
| Svetlana Lucas | JSPR | Common Stock Warrant (right to buy) | Purchase | 20,000 | 20,000 | 22 Sep 2025 | Direct | |||
| Ron Martell | JSPR | Voting Common Stock | Purchase | 123.8% | $99,630 | $2.43 | 41,000 | 74,118 | 22 Sep 2025 | Direct |
| Ron Martell | JSPR | Common Stock Warrant (right to buy) | Purchase | 41,000 | 41,000 | 22 Sep 2025 | Direct | |||
| Judith Anne Shizuru | JSPR | Voting Common Stock | Purchase | 35.4% | $99,630 | $2.43 | 41,000 | 156,901 | 22 Sep 2025 | Direct |
| Judith Anne Shizuru | JSPR | Common Stock Warrant (right to buy) | Purchase | 41,000 | 41,000 | 22 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.